Cao QY, Li Z. Evolving of treatment options for cerebral infarction. World J Clin Cases 2024; 12(32): 6534-6537 [DOI: 10.12998/wjcc.v12.i32.6534]
Corresponding Author of This Article
Zheng Li, PhD, Lecturer, Pharmacist, Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, No. 101 Shanghai Road, Xuzhou 221000, Jiangsu Province, China. lizhengcpu@163.com
Research Domain of This Article
Pharmacology & Pharmacy
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 16, 2024; 12(32): 6534-6537 Published online Nov 16, 2024. doi: 10.12998/wjcc.v12.i32.6534
Evolving of treatment options for cerebral infarction
Qiong-Yue Cao, Zheng Li
Qiong-Yue Cao, School of Life Sciences, Jiangsu Normal University, Xuzhou 221116, Jiangsu Province, China
Zheng Li, Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, Xuzhou 221116, Jiangsu Province, China
Author contributions: Cao QY contributed to analysis of data, drafting the article, and providing final approval; Li Z contributed to design of the study, revising the article, and providing final approval.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zheng Li, PhD, Lecturer, Pharmacist, Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, No. 101 Shanghai Road, Xuzhou 221000, Jiangsu Province, China. lizhengcpu@163.com
Received: June 11, 2024 Revised: July 26, 2024 Accepted: July 31, 2024 Published online: November 16, 2024 Processing time: 105 Days and 0.5 Hours
Abstract
In this editorial, we comment on a recent article which addressed the therapeutic effect of aspirin plus edaravone in patients with cerebral infarction (CI). Herein, we outline the progress in therapy of CI. Apart from thrombolysis, aspirin is the most effective treatment for CI. Edaravone, a free radical scavenger, reduces endothelial cell damage and delays neuronal cell death. Aspirin plus edaravone mitigates damage to brain tissue by different mechanisms, thereby expediting the reinstation of neurological function. However, the nephrotoxic effect of edaravone, along with gastrointestinal bleeding associated with aspirin, may restrict this combination therapy. Although clinical studies have demonstrated the efficacy of thrombolytic therapy and mechanical thrombectomy, patients receiving these treatments experience modest efficacy and many adverse events. Moreover, interest in exploring natural medicines for CI is increasing, and they appear to have a high potential to protect against CI. The evolution of therapeutic strategies is expected to improve clinical outcomes of patients with CI.
Core Tip: In the last few decades, the treatment of cerebral infarction (CI) has seen a dramatic evolution of pharmacological drugs. This editorial focuses on the progress in treatment options for CI. We hope that it will provide valuable information for the treatment of CI.
